PURPOSE End-organ apoptosis is well-described in progressive sepsis and Multiple Organ Dysfunction Syndrome (MODS), especially where platelets accumulate (e.g. spleen and lung). We previously reported an acute sepsis-induced cytotoxic platelet phenotype expressing serine protease granzyme B. We now aim to define the site(s) of and mechanism(s) by which platelet granzyme B induces end-organ apop...

BACKGROUND AND PURPOSE Intraprocedural thrombus formation during endovascular treatment of intracranial aneurysms is often treated with glycoprotein IIb/IIIa inhibitors and, in some instances, fibrinolytic therapy. We performed a meta-analysis evaluating the safety and efficacy of GP IIb/IIIa inhibitors compared with fibrinolysis. We also evaluated the safety and efficacy of abciximab, an irrev...

BACKGROUND There is some controversy as to whether tirofiban or eptifibatide, two small anti-aggregating drugs (AAD), may reduce the incidence of composite ischemic events within one year in patients undergoing percutaneous coronary intervention (PCI) in the real clinical world. METHODS We compared consecutive patients on oral double AAD (with clopidogrel and aspirin) who underwent PCI (n=207...

[This corrects the article on p. 603 in vol. 10, PMID: 25120366.].

Abstract Background A tracheo-innominate fistula is a rare but life-threatening complication of tracheostomy and has mortality rate 100% without therapy. The underlying cause an acquired between the brachiocephalic trunk trachea, induced by cannula’s mechanical impact. Case presentation 25-year-old female was admitted with pulsatile bleeding from tracheostomy. artery fistula, which difficult to...

New strategies for profound inhibition of platelet activity at the injured coronary plaque focus on blockade of the platelet surface membrane glycoprotein IIb/IIIa receptor, which binds circulating fibrinogen or von Willebrand factor and crosslinks platelets as the final common pathway to platelet aggregation. Intravenous agents directed against this receptor include the chimeric monoclonal ant...